SCHEMBL6033869

SCHEMBL6033869

CCCCCC(C)c1cccc2c1C(=O)NC2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GSK3B P49841 2/20 0.35
CASP3 P42574 2/20 0.35
CASP2 P42575 1/20 0.35
CASP7 P55210 1/20 0.35
CASP6 P55212 1/20 0.35
CASP8 Q14790 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
GPR84 Q9NQS5 2/20 0.35
PARP1 P09874 1/20 0.34
CHEK1 O14757 1/20 0.34
POLM Q9NP87 1/20 0.33
POLK Q9UBT6 1/20 0.33
POLL Q9UGP5 1/20 0.33
POLH Q9Y253 1/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10731506 0.86 CYSLTR2 (0.39) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL10384426 0.84 KDM4E (0.40) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL28620531 0.83 KDM4E (0.37) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL8356651 0.83 KDM4E (0.43) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL8815302 0.82 MEN1 (0.37) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL30608966 0.82 KDM4E (0.36) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL4909210 0.80 ALDH1A1 (0.38) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL9136212 0.80 ALDH1A1 (0.38) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL6285442 0.80 KDM4E (0.38) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL10986102 0.79 KDM4E (0.42) KDM4EALDH1A1HPGDGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687642-A2 ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS CENTELION (FR) 2006-08-09 EP disclosed
WO-2005038465-A2 ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS CENTELION (FR) 2005-04-28 WO disclosed